Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/69866
DC FieldValueLanguage
dc.contributor.authorReck, Martinen_US
dc.contributor.authorRodríguez Abreu, Delvysen_US
dc.contributor.authorRobinson, Andrew G.en_US
dc.contributor.authorHui, Rinaen_US
dc.contributor.authorCsoszi, Tiboren_US
dc.contributor.authorFülöp, Andreaen_US
dc.contributor.authorGottfried, Mayaen_US
dc.contributor.authorPeled, Niren_US
dc.contributor.authorTafreshi, Alien_US
dc.contributor.authorCuffe, Sineaden_US
dc.contributor.authorO’Brien, Maryen_US
dc.contributor.authorRao, Sumanen_US
dc.contributor.authorHotta, Katsuyukien_US
dc.contributor.authorVandormael, Kristelen_US
dc.contributor.authorRiccio, Antonioen_US
dc.contributor.authorYang, Jingen_US
dc.contributor.authorCatherine Pietanza, M.en_US
dc.contributor.authorBrahmer, Julie R.en_US
dc.date.accessioned2020-02-05T12:50:53Z-
dc.date.available2020-02-05T12:50:53Z-
dc.date.issued2019en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/69866-
dc.description.abstractPURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab. PATIENTS AND METHODS Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks (for up to 2 years) or investigator’s choice of platinum-based chemotherapy (four to six cycles). Patients assigned to chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary end point was progression-free survival; OS was an important key secondary end point. Crossover adjustment analysis was done using the following three methods: simplified two-stage method, rank-preserving structural failure time, and inverse probability of censoring weighting. RESULTS Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n = 151). At data cutoff (July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm and 96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not reached) with pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard ratio, 0.63; 95% CI, 0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to receive pembrolizumab. When adjusted for crossover using the two-stage method, the hazard ratio for OS for pembrolizumab versus chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving structural failure time and inverse probability of censoring weighting were similar. Treatment-related grade 3 to 5 adverse events were less frequent with pembrolizumab compared with chemotherapy (31.2% v 53.3%, respectively). CONCLUSION With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.sourceJournal of Clinical Oncology [ISSN 0732-183X], v. 37 (7), p. 537-546en_US
dc.subject320101 Oncologíaen_US
dc.subject.otherTrials
dc.subject.otherSurvival
dc.titleUpdated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greateren_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1200/JCO.18.00149
dc.identifier.scopus85064128148-
dc.identifier.isi000460356200002
dc.contributor.authorscopusid7004331368-
dc.contributor.authorscopusid23989750700-
dc.contributor.authorscopusid57208810486-
dc.contributor.authorscopusid7006029366-
dc.contributor.authorscopusid55949490500-
dc.contributor.authorscopusid57191920353-
dc.contributor.authorscopusid23027420400-
dc.contributor.authorscopusid8920831500-
dc.contributor.authorscopusid57191923347-
dc.contributor.authorscopusid26221722800-
dc.contributor.authorscopusid57191461334-
dc.contributor.authorscopusid57191919664-
dc.contributor.authorscopusid35401967200-
dc.contributor.authorscopusid6602907680-
dc.contributor.authorscopusid57208209631-
dc.contributor.authorscopusid57202386272-
dc.contributor.authorscopusid57189233768-
dc.contributor.authorscopusid6507427248-
dc.description.lastpage546-
dc.identifier.issue7-
dc.description.firstpage537-
dc.relation.volume37-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid15815
dc.contributor.daisngid1064006
dc.contributor.daisngid1128491
dc.contributor.daisngid30184843
dc.contributor.daisngid1270853
dc.contributor.daisngid2664090
dc.contributor.daisngid28125077
dc.contributor.daisngid60442
dc.contributor.daisngid797865
dc.contributor.daisngid179290
dc.contributor.daisngid31444429
dc.contributor.daisngid4197838
dc.contributor.daisngid4434
dc.contributor.daisngid1395972
dc.contributor.daisngid1013288
dc.contributor.daisngid29754675
dc.contributor.daisngid305985
dc.contributor.daisngid68971
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Reck, M
dc.contributor.wosstandardWOS:Rodriguez-Abreu, D
dc.contributor.wosstandardWOS:Robinson, AG
dc.contributor.wosstandardWOS:Hui, RN
dc.contributor.wosstandardWOS:Csoszi, T
dc.contributor.wosstandardWOS:Fulop, A
dc.contributor.wosstandardWOS:Gottfried, M
dc.contributor.wosstandardWOS:Peled, N
dc.contributor.wosstandardWOS:Tafreshi, A
dc.contributor.wosstandardWOS:Cuffe, S
dc.contributor.wosstandardWOS:O'Brien, M
dc.contributor.wosstandardWOS:Rao, S
dc.contributor.wosstandardWOS:Hotta, K
dc.contributor.wosstandardWOS:Vandormael, K
dc.contributor.wosstandardWOS:Riccio, A
dc.contributor.wosstandardWOS:Yang, J
dc.contributor.wosstandardWOS:Pietanza, MC
dc.contributor.wosstandardWOS:Brahmer, JR
dc.date.coverdateMarzo 2019
dc.identifier.ulpgces
item.grantfulltextnone-
item.fulltextSin texto completo-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

366
checked on May 16, 2021

WEB OF SCIENCETM
Citations

350
checked on May 16, 2021

Page view(s)

33
checked on May 17, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.